Redeye is bullish after the strong numbers from the NeoLIPA readout presented this morning. The primary endpoint, pathological complete response, exceeded 40% which we had previously defined as a success.
ANNONS
Redeye is bullish after the strong numbers from the NeoLIPA readout presented this morning. The primary endpoint, pathological complete response, exceeded 40% which we had previously defined as a success.
